elranatamab
pfizer
['magnetismm-1', 'multiplemyeloma', 'elranatamab']
#ash22 in the magnetismm-1 trial, #elranatamab induced durable clinical and molecular responses in patients with relapsed or refractory #multiplemyeloma (#mm) 
A magazine from @ASH_Hematology offering news and views for the broader hematology/oncology community.